|Bid||31.46 x 1400|
|Ask||31.49 x 3200|
|Day's Range||30.54 - 31.59|
|52 Week Range||10.52 - 32.44|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.39|
Nicholas Nash, the former president of Singapore-based online gaming and e-commerce company Sea Ltd, has launched a private equity firm - Asia Partners - to invest in Southeast Asian technology start-ups. Asia Partners' four other co-founders include Oliver Rippel, a former senior executive of South Africa's Naspers, and Pitra Ciputra Harun, who was previously with Indonesian e-commerce company Bukalapak, according to the company statement on Friday. The private equity firm aims to make investments of between $20 million and $100 million.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Despite the market's drubbing since late April, stocks are still up for the year. Some stocks, in fact, are still well up since the end of 2018. The best stocks for 2019 so far have been buoyed by strong backstories, impressive results or just an inordinate amount of rampant speculation.Regardless of the reason, that raw strength is worth a closer look. These big winners may be in the midst of unstoppable rallies, making these names some of the best stocks to buy for what looks like a rather rough summer. Or it's just as possible these big rallies have set up equally big selloffs, and profit-takers are ready plow in. * 6 Big Dividend Stocks to Buy as Yields Plunge While these may be the best stocks of 2019 so far in terms of performance, notice how few of them are mainstream or household names. Maybe being off the radar -- or working on an unbeatable business -- is the key to shrugging off marketwide lethargy.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Array Biopharma (ARRY)Source: Shutterstock YTD Gain: 97%Array Biopharma (NASDAQ:ARRY) has been the beneficiary of not one but two waves of great news this year, fueling two incredible surges. In January shares rallied on the heels of a successful phase 3 trial of one of its colon cancer therapies. Then, in May, ARRY stock popped again when the same combination therapy showed tremendous promise as a treatment for advanced melanoma.Though Array Biopharma is growing the top line at a strong double-digit rate, it's at a stage where the bigger the company gets, the more money it loses. It's going to need to lot more scale to get into the black, and that may not happen for a long while.Though analysts love ARRY for its story and potential, the current price is already very near the consensus target of $28.80. And the pros haven't seemed interested in upping that target. Sinclair Broadcast Group (SBGI)Source: Flash.pro via Flickr (modified)YTD Gain: 104%To be fair, shares of Sinclair Broadcast Group (NASDAQ:SBGI) started the new year out with something of an advantage for this list. SBGI has spent four straight years spinning its wheels, with SBGI stock making no net progress between the end of 2013 and late 2018. * 7 Stocks to Sell Impacted by the Mexican Tariffs The company may be one of the few traditional television outfits that's positioned to survive the cord-cutting phenomenon though. Sinclair is the company that bought most of the regional sports networks Walt Disney (NYSE:DIS) owned after it acquired Fox. It rallied leading into the news on speculation that it would happen, but continued to rally after the announcement on chatter that it was already thinking about distribution deals through non-traditional venues like Amazon.com (NASDAQ:AMZN). Iovance Biotherapeutics (IOVA)Source: (C)iStock.com/AlexRaths YTD Gain: 104%Despite being one of the best stocks of 2019 when looking at returns, biotech company Iovance Biotherapeutics (NASDAQ:IOVA) is pre-profit. In fact, it's pre-revenue. A handful of investors are enthused about its pipeline though, and particularly Lifileucel as a treatment for melanoma. It's in late-stage trials right now and looking very promising.At the same time, a recent update on its investigator-sponsored trial of LN-145 as a treatment of cervical cancer has also been well received.Of that testing, Emese Zsiros, M.D., Ph.D. and observer of the trial in question commented "The observation in the study of LN-145 that median DOR has not yet been reached at a median of 7.4 months following treatment provides evidence that this therapy could provide a clinically meaningful improvement over currently available options for patients with advanced cervical cancer."For the first time ever, Iovance Biotherapeutics is nearing a developmental endzone… a couple of endzones, actually. Guardant Health (GH)Source: Shutterstock YTD Gain: 108%Guardant Health (NASDAQ:GH) is not just one of this year's biggest winners and best stocks. It's also been one of the hottest IPOs of late. Only going public in early October, shares are already up an incredible 300%, and have gained more than 100% since the end of calendar 2018.Guardant Health is a developer of a handful of highly-focused oncology diagnostics tests. By digging deeper into genomic information, the company identifies which cancer treatment regimen would be most effective for a particular patient. Its technology has even proven useful for pharmaceutical developers looking to pinpoint genomic data that leads to better drug-testing outcomes. * 9 Trade War Stocks to Sell on U.S.-China Deal News The organization isn't profitable yet, but its strong revenue growth pace is leading to smaller and smaller losses that put Guardant Health on a path to profits in the foreseeable future. Mirati Therapeutics (MRTX)Source: Shutterstock YTD Gain: 110%Coming into the year, Mirati Therapeutics (NASDAQ:MRTX) was already on a bullish rampage more than doubling in 2018 thanks to progress with its pipeline.The lead drug is sitravatinib -- an immuno-oncology agent that, when used in conjunction with an anti-PD-1 checkpoint inhibitor drug Opdivo, shows promise as a second-line treatment for non-small-cell lung cancer. That phase 3 trial should be starting soon. The drug appeared to crash and burn given October's updated data, but another round of testing could still salvage that work.In the meantime, MRTX jumped more than 30% on Monday after rival drug company Amgen (NASDAQ:AMGN) offered an update on a drug similar to sitravatinib that validates sitravatinib itself.While encouraging, the total advance since mid-2017 looks and feels overextended. Though its been one of the best stocks of 2019 so far, I don't think the back half of the year holds much promise. Avalara (AVLR)Source: 401(k) 2012 via FlickrYTD Gain: 110%Avalara (NYSE:AVLR) is a software company with a good-sized suite of product, but its claim to fame and flagship is a sales tax-calculation tool that's become enormously important now that more and more states are enforcing the collection of sales tax on interstate e-commerce transactions.Sales growth hasn't been a problem. This year's projected top-line improvement of 28% extends a long-standing streak, and the pros are calling for comparable revenue growth this year. Where Avalara falls short is on the earnings front. Despite strong sales growth for years now, the company remains in the red… but not for much longer. If all goes as planned, this year's estimated loss of 18 cents per share following last year's loss of 67 cents should swing to a profit of eight cents per share. * 7 Stocks to Sell in June With operating earnings in sight, AVLR is up 110% so far this year, making it one of 2019's very best stocks to own. Snap (SNAP)Source: Shutterstock YTD Gain: 112%Shares of Snap (NYSE:SNAP) are up big time this year, but it's a gain with a major asterisk. That is, the triple-digit gain since late last year is a reclamation of the massive amount of ground SNAP stock lost in 2018. Even with that bullish move, SNAP stock is still only trading at about two-thirds of its early 2017 IPO price.Still, credit has to be given where it's due. The rebound rally was inspired by last quarter's smaller-than-expected loss and renewed progress in the number of daily users logging into the app.That said, more user growth could be in the cards now that the company recognizes simply have a communication platform isn't enough. It's starting to innovate in a big way, with the most recent idea being working directly with record labels to improve how music can be used in the app. Sea Limited (SE)Source: Shutterstock YTD Gain: 147%Sea Limited (NYSE:SE) offers several different types of digital entertainment to eastern Asian consumers -- particularly outside of China. But mobile and PC games along with eSports and e-commerce services are its core operations. Sea is best known, however, for its mobile wallet app called AirPay.It's been growing like crazy too. Though still booking losses (and likely to continue doing so for a few more years), sales are estimated to rise by almost 100% this year, and grow another 40% next year. The company has found its place, and stride. * 6 Big Dividend Stocks to Buy as Yields Plunge Nevertheless, this might be a rally to be wary of. While analysts will often up their consensus target as a stock rises, the current price near $28 is above a seemingly stagnant price target of just under $27. Spark Therapeutics (ONCE)Source: Shutterstock YTD Gain: 178%Take the huge 178% gain Spark Therapeutics (NASDAQ:ONCE) has dished out this year with a grain of salt. It all almost happened in one shot. In late February ONCE stock soared on the heels of news that drug company Roche (OTCMKTS:RHHBY) had made a very generous acquisition offer.The deal hasn't been consummated yet, and the FTC still needs to give it the green light. But, Roche says it expects the offer to be finalized and accepted before the end of the month.While it's unlikely the intended pairing will be derailed at this point, on the off chance it does, know that Roche's interest wasn't just Spark's Luxterna -- though it's the FDA's first-ever gene therapy treatment for a retinal disease that often leads to blindness. But ONCE's underlying gene therapy science has value well beyond that one application. Roku (ROKU)Source: Roku YTD Gain: 193%Finally, this year's biggest winner has been Roku (NASDAQ:ROKU), up almost 200% in just a little over five months.Like several other of the oversized gains we've seen since the end of 2018, Roku had the benefit of coming out of an oversized pullback during the last few months of last year. Nevertheless, the stock's earned every bit of its current price near $90.Roku, of course, is the name behind what's become the world's most popular streaming video receiver, dethroning several other (and bigger) consumer-tech companies that arguably should have been able to keep the young company at bay. * 7 Stocks to Sell Impacted by the Mexican Tariffs Whatever the case, this year's big move coincides with the company's discovery of several winning formulas and initiatives. Namely, Roku has figured out it can make even more money by selling ad space through its devices than just selling devices themselves. In that the latter fuels the former though, the pros are calling for an amazing 41% increase in this year's sales to be followed by 33% growth next year.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post The 10 Best Stocks for 2019 -- So Far appeared first on InvestorPlace.
SHENZHEN, China/SHANGHAI, May 28 (Reuters) - When Tencent Holdings Ltd made its first big foray overseas with an adaptation of its blockbuster mobile game "Honour of Kings" in the summer of 2017, executives thought they had a sure-fire success on their hands. The multi-player role-playing game, in which players hack and slash their way through battle arenas, had 55 million daily active users in China and was raking in roughly $145 million a month, making it the company's top grossing game. Tencent has now all but written off its original plans for "Arena of Valor" and disbanded the game's marketing team for Europe and the United States, two company sources with direct knowledge of the matter said.
SHENZHEN, China/SHANGHAI (Reuters) - When Tencent Holdings Ltd made its first big foray overseas with an adaptation of its blockbuster mobile game "Honour of Kings" in the summer of 2017, executives thought they had a sure-fire success on their hands. The multi-player role-playing game, in which players hack and slash their way through battle arenas, had 55 million daily active users in China and was raking in roughly $145 million a month, making it the company's top grossing game. But missteps in development and marketing, exacerbated by a rift with Tencent's U.S.-based Riot Games subsidiary, has seen the international version, called "Arena of Valor", flop in Europe and North America.
Looking for fresh investing inspiration? Look no further. Hedge funds have just revealed their trades for the first quarter of 2019. This means we can see which stocks the ‘Smart Money’ is buying and selling right now. In this case, we used TipRanks algorithms to look at a large set of hedge funds and measure their exposure to each stock trading on the NASDAQ and NYSE. The following five stocks all score very highly on this basis. What’s more, all five stocks also boast the Street’s seal of approval with a ‘Strong Buy’ consensus based on all ratings received over the last three months. Interestingly, it appears that hedge funds are bullish on the market outlook despite fraught relationships between the US and China. “It would appear that the majority of hedge funds do not expect another sharp rise in volatility, and that they have concluded that the correction has run its course,” Nomura strategist Masanari Takada wrote.With this in mind let’s now take a closer look at five ‘Strong Buy’ hedge fund stock picks from 1Q19: Fiserv Inc (FISV – Research Report) Fiserv is a leading US provider of financial services technology. Year-to-date this is a stock that has performed strongly, with shares surging 19%. And according to analysts, the company is primed to continue outperforming. Indeed Fiserv has just announced a $22 billion acquisition of First Data Corp (FDC)- creating an impressive payments and fintech behemoth. The pending all-stock merger is expected to close in the second half of the year. First Data secures and processes more than 3,000 transactions per second and $2.4 trillion per year. Oppenheimer’s Glenn Greene is the 4 analyst on TipRanks out of over 5,000 tracked analysts. He is bullish on FISV stock, reiterating his buy rating after the deal was announced, and after Fiserv reported solid 1Q earnings results. “We remain attracted to FISV’s business model and long-term prospects and are highly enthusiastic about FISV’s pending merger with FDC, which should generate significant (>$1.4B) revenue/cost synergies, and related EPS accretion, over the next five years. Trading at 19x our FY20E pro forma EPS estimate including FDC, shares appear attractive” the analyst explained.View FISV Price Target & Analyst Ratings Detail Twilio Inc (TWLO – Research Report) Cloud communications platform Twilio also boasts notably positive hedge fund sentiment. Twilio allows software developers to programmatically make and receive phone calls, send and receive text messages, and perform other communication functions using its web service APIs.Luckily for hedge funds, shares have exploded by 54% year-to-date and 11% in the last five days alone. According to five-star Oppenheimer analyst Ittai Kidron, Twilio still has room to run given its ‘elongated high-growth trajectory.’ He has just carried out a deep-dive analysis of Twilio following the SendGrid merger, writing “our analysis yet again leaves us bullish and illustrates the upside left in the model, especially in 2H19/2020.”This is a company that benefits from the rapid adoption of application-to-person (A2P) communication; 2) a large and growing market as communication options expand (voice, SMS, video, etc.); and 3) a successful developer-focused sales model. “Overall, we believe these elements will enable Twilio to continue to experience strong revenue growth for the foreseeable future and drive upside to consensus expectations” concludes the analyst. View TWLO Price Target & Analyst Ratings Detail Sea Limited (SE – Research Report) If you haven’t head of Sea Limited before, this is a major Southeast Asia Internet company operating three popular online platforms. These focus on digital entertainment (Garena, gaming), eCommerce (Shopee, a third-party marketplace), and digital financial services (AirPay, e-wallet services). “Sea operates an established, profitable asset with its Garena segment that should help fund investments in its developing businesses (Shopee, AirPay) as they scale and gain market share” cheers Top 50 Stifel Nicolaus analyst Scott Devitt. He has a buy rating on SE with a $32 price target (24% upside potential).Devitt is confident going into the print later today, thanks to checks that indicate strong momentum for SE’s Free Fire video game. “While Free Fire’s user base is mobile-only and skews heavily to emerging markets, we continue to view the monetization potential as attractive” writes the analyst. Net-net: “With leverage to strong emerging growth markets and leading market positions, we recommend Sea as an investment idea.”He isn’t the only one. This is a stock with four back-to-back buy ratings from the Street:View SE Price Target & Analyst Ratings Detail Haemonetics Corp (HAE – Research Report) Haemonetics is a global provider of blood and plasma supplies. Its NexSys PC system is designed to enable organizations to collect more plasma with every donation. Shares are trading up 20% in the last month after a solid earnings beat in terms of profitability. What’s more, management provided strong financial guidance for FY/20, particularly in terms of non-GAAP EPS and cash flows.“We continue to view HAE as one of the best ideas in our coverage universe” enthuses Barrington Research’s Michael Petusky. He has just reiterated his HAE buy rating with a $116 price target (16% upside potential). “We continue to be very optimistic in terms of HAE’s key growth drivers (plasma and hospital) and remain quite bullish regarding the company’s ability to execute against its complexity reduction initiative goals. If the company was able to land any additional and sizable agreements connected to its NexSys PCS conversion activities, material additional upside to our estimates would be likely” explains Petusky. Meanwhile Raymond James’ Lawrence Keusch has just upgraded HAE from hold to buy, citing “a path towards 21% EPS growth over the next two years.”View HAE Price Target & Analyst Ratings Detail Regency Centers Corp (REG – Research Report) Last but not least comes Regency Centers. This Florida-based real estate investment trust (REIT) is one of the largest operators of grocery-anchored shopping centers. It is also one of RBC Capital’s favorite stock picks. “REG remains our top idea for retail despite noise from starting larger redevelopments” states the firm’s Wes Golladay. This top-ranked analyst recently reiterated his bullish call on REG with a $72 price target.“We believe Regency Centers remains well positioned for above-average long-term FFO/growth. The centers remain well leased, which should lead to optimal merchandising of centers and favorable pricing power on the organic front” writes the analyst. What’s more the company’s development platform should provide an additional layer of growth, and cash flow. That’s with a balance sheet that positions REG to be opportunistic should there be increased dislocation in retail real estate. “Regency has one of the best development platforms, in our opinion, which should lead to above-average development activity vs. the peer group” writes Golladay. View REG Price Target & Analyst Ratings Detail Find your own ‘Strong Buy’ stocksHere we covered hedge funds' top stock picks. Hedge fund sentiment is just one datapoint covered in the TipRanks' Smart Score. This new feature brings together all of TipRanks' unique insights- from hedge funds to insiders to bloggers- to give stocks a score out of 10. You can find 'Strong Buy' stocks with a 'perfect' score of 10 here.
Insider Monkey recently shared Tollymore Investment Partners' May 2019 Investor Letter, in which the fund reported delivering an annualized return of 21% since inception. You can track down a copy of its letter here. In the letter, the fund also shared a thorough analysis of Sea Limited (NYSE:SE) writing the following: "In March 2019 we […]
SINGAPORE , May 2, 2019 /PRNewswire/ -- Sea Limited (NYSE: SE) ("Sea" or the "Company") today announced that its Group General Counsel and Company Secretary, Yanjun Wang , has assumed ...
SINGAPORE , May 2, 2019 /PRNewswire/ -- Sea Limited (NYSE: SE) ("Sea" or the "Company") plans to announce its first quarter 2019 results after the U.S. market closes on May 21, 2019 ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! When you buy shares in a company, there is always a risk that the price drops to zero. But if yo...
It is Monday morning and things started slowly, but the buyers are out there. FAANG names are mixed, but small-caps are exhibiting very good relative strength for the second day in a row and are currently at a new closing high for the year. The group had been the laggard, but it has improved nicely as market players are willing to take on higher levels of risk.
At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]
Stock indexes: Singapore-based Sea Limited advanced almost 3% in strong volume. Sea Limited is a 2017 initial public offering.
HENDERSON, NV / ACCESSWIRE / April 12, 2019 / Artificial Intelligence in business is a hot topic in the investing world - so hot that some companies are using the term for a PR boost. But make no mistake, ...
HENDERSON, NV / ACCESSWIRE / April 9, 2019 / The top performing sector in Q1 was technology. Positive sentiment surrounding US/China trade talks and consumer activity has helped keep confidence high. Additionally, ...
When you read the description of this company, it really checks a lot of the hot buttons in the market. Fintech. eSports. E-commerce. Digital payments. You really couldn't ask for more under one roof.